Clene Inc ( (CLNN) ) has released its Q3 earnings. Here is a breakdown of the information Clene Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clene Inc. is a clinical-stage pharmaceutical company focused on developing nanotechnology therapeutics for neurological disorders, including ALS, MS, and Parkinson’s disease. In its latest earnings report, Clene Inc. revealed a continued struggle with financial losses, reporting a net loss of $8.8 million for the third quarter of 2025, compared to a $8.0 million loss in the same period last year. The company’s revenue remained minimal, with only $15,000 generated in the quarter, highlighting its ongoing reliance on external funding to support its operations. Clene’s financial position showed a decrease in cash and cash equivalents to $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. The company also reported a significant stockholders’ deficit, which increased to $12.4 million by the end of the third quarter. Looking ahead, Clene Inc. faces substantial challenges in securing additional financing to continue its operations and advance its drug development programs. The management has implemented cost-saving measures and is exploring various funding options, but the company’s future remains uncertain as it seeks to overcome its financial hurdles.